Literature DB >> 17149588

Comment on: Weickert MO, Pfeiffer AFH (2006) Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49:1732-1741.

R N A Black, P M Bell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17149588     DOI： 10.1007/s00125-006-0550-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.

Authors:  R S Elkeles; J R Diamond; V Anyaoku; C Hughes; W Richmond
Journal:  Atherosclerosis       Date:  1999-09       Impact factor: 5.162

Review 2.  Signalling mechanisms linking hepatic glucose and lipid metabolism.

Authors:  M O Weickert; A F H Pfeiffer
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

3.  Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.

Authors:  M Guerre-Millo; P Gervois; E Raspé; L Madsen; P Poulain; B Derudas; J M Herbert; D A Winegar; T M Willson; J C Fruchart; R K Berge; B Staels
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

4.  Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.

Authors:  Elisabeth Cavallero; Christiane Dachet; Farideh Assadolahi; Claude Martin; Nicole Navarro; Jean-Claude Ansquer; Christophe Corda; Christelle Foucher; Irene Juhan-Vague; Bernard Jacotot
Journal:  Atherosclerosis       Date:  2003-01       Impact factor: 5.162

5.  Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.

Authors:  M Kobayashi; Y Shigeta; Y Hirata; Y Omori; N Sakamoto; S Nambu; S Baba
Journal:  Diabetes Care       Date:  1988-06       Impact factor: 19.112

6.  Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.

Authors:  A Avogaro; M Miola; A Favaro; L Gottardo; G Pacini; E Manzato; S Zambon; D Sacerdoti; S de Kreutzenberg; T Piliego; A Tiengo; S Del Prato
Journal:  Eur J Clin Invest       Date:  2001-07       Impact factor: 4.686

7.  Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.

Authors:  A Hernández-Mijares; I Lluch; E Vizcarra; M L Martínez-Triguero; J F Ascaso; R Carmena
Journal:  Nutr Metab Cardiovasc Dis       Date:  2000-02       Impact factor: 4.222

8.  The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.

Authors:  M W Stewart; R G Dyer; K G Alberti; M F Laker
Journal:  Diabet Med       Date:  1995-03       Impact factor: 4.359

9.  Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

Authors:  H Vuorinen-Markkola; H Yki-Järvinen; M R Taskinen
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

10.  A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.

Authors:  M Ohrvall; H Lithell; J Johansson; B Vessby
Journal:  Metabolism       Date:  1995-02       Impact factor: 8.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.